Discussion: And The Science Says…

Matthew Powell, MD
Washington University, St. Louis, Missouri, USA

Floor Backes, MD
The Ohio State University, James Cancer Center, Columbus, Ohio, USA

Amanda Nickles Fader, MD
Johns Hopkins University, Baltimore, Maryland, USA
Patient Case #1

Case Overview

• 57-year-old patient with IIIC grade 1 endometrioid endometrial cancer (pMMR, ER/PR+, p53wt, HER2 1+)
• Now with recurrent pMMR endometrial cancer with peritoneal carcinomatosis.
• She completed adjuvant carboplatin/paclitaxel/IO on trial 6 months ago.
Patient Case #2

Case Overview

- 57-year-old patient with IIIC1 serous uterine cancer
- Now with recurrent pMMR, p53mut, HER2 3+ endometrial cancer with peritoneal carcinomatosis.
Patient Case #3

Case Overview

- 57-year-old patient with IIIC grade 1 endometrioid endometrial cancer (dMMR, ER/PR+, p53wt, HER2 1+)
- Now with recurrent dMMR endometrial cancer with a new LUQ/splenic flexure 3 cm mass.
- She completed adjuvant carboplatin/paclitaxel/IO on trial and completed maintenance IO 4 months ago.
1L advanced/metastatic endometrial cancer

New treatment paradigm

- **MMRd**
  - Mutation
    - Chemo+IO
    - IO alone?
  - Methylation
    - Chemo+IO
    - IO alone?

- **MMRp**
  - P53abn
    - Chemo+bev
    - +/- IO?
  - HER2
    - Chemo+HER2 targeting
    - +/- IO?
    - Chemo+IO+PARPi
    - Chemo→PARPi?
    - Exportin 1 inhibitor?
    - Chemo→Exportin 1 inhibitor?

- **POLEmut**
- **Observation?**

- **NSMP**
  - HRD pos
    - P53wt
    - Exportin 1 inhibitor?
  - HRD neg
    - P53wt
    - Hormonal therapy combinations

1L advanced/metastatic endometrial cancer